LUNA-18

Oncology

Also known as: LUNA18

Macrocyclic PeptidesResearch phase: Phase 1Regulatory: Not approved. Investigational for KRAS-mutant solid tumors.

Mechanism

LUNA-18 is a macrocyclic peptide inhibitor targeting KRAS G12C and G12D mutations, which are among the most common oncogenic drivers. It is in Phase 1 trials for advanced solid tumors.

Technical detail

LUNA-18 is an orally bioavailable macrocyclic peptide inhibitor of KRAS G12C and G12D mutants developed using a proprietary peptide macrocycle platform. It binds the switch II pocket of KRAS and inhibits both active (GTP-bound) and inactive (GDP-bound) states. Phase 1 dose escalation is ongoing in KRAS-mutant NSCLC, colorectal cancer, and pancreatic cancer, with preliminary antitumor activity reported.

Build a personalized protocol with LUNA-18 →